$1.52 Billion is the total value of Bellevue Group AG's 138 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 20.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CI | Sell | CIGNA CORPORATION | $31,456,000 | -10.9% | 165,625 | -2.3% | 2.07% | -7.6% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $24,170,000 | -45.2% | 157,797 | -37.7% | 1.59% | -43.2% |
| HUM | Sell | HUMANA INC | $22,535,000 | -32.4% | 78,660 | -20.2% | 1.48% | -29.9% |
| BAX | Sell | BAXTER INTL INC | $16,754,000 | -17.5% | 254,543 | -3.3% | 1.10% | -14.4% |
| WBA | Sell | WALGREENS BOOTS ALLIANCE INC | $15,224,000 | -7.6% | 222,802 | -1.4% | 1.00% | -4.2% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $15,157,000 | -40.4% | 155,680 | -15.0% | 1.00% | -38.2% |
| PRAH | Sell | PRA HEALTH SCIENCES INC | $13,086,000 | -28.6% | 142,300 | -14.5% | 0.86% | -26.1% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $11,464,000 | -41.1% | 345,100 | -10.7% | 0.75% | -38.9% |
| CNC | Sell | CENTENE CORP DEL | $10,389,000 | -67.1% | 90,101 | -58.7% | 0.68% | -65.9% |
| GILD | Sell | GILEAD SCIENCES INC | $7,694,000 | -27.5% | 123,000 | -10.5% | 0.51% | -24.8% |
| BIIB | Sell | BIOGEN INC | $7,598,000 | -45.2% | 25,250 | -35.7% | 0.50% | -43.2% |
| RMD | Sell | RESMED INC | $6,307,000 | -41.3% | 55,392 | -40.6% | 0.42% | -39.1% |
| HMSY | Sell | HMS HLDGS CORP | $6,099,000 | -18.1% | 216,817 | -4.5% | 0.40% | -15.2% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $5,677,000 | -44.9% | 15,200 | -40.3% | 0.37% | -42.9% |
| MYL | Sell | MYLAN N V | $5,396,000 | -73.9% | 196,950 | -65.2% | 0.36% | -73.0% |
| QTRX | Sell | QUANTERIX CORP | $5,235,000 | -22.0% | 285,907 | -8.7% | 0.34% | -19.2% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $3,914,000 | -15.7% | 45,969 | -4.0% | 0.26% | -12.6% |
| HOLX | Sell | HOLOGIC INC | $3,699,000 | -75.1% | 90,000 | -75.1% | 0.24% | -74.2% |
| HZNP | Sell | HORIZON PHARMA PLC | $3,292,000 | -24.1% | 168,500 | -24.0% | 0.22% | -21.5% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $2,860,000 | -44.0% | 40,050 | -3.6% | 0.19% | -42.0% |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $2,333,000 | -23.5% | 23,148 | -4.1% | 0.15% | -21.1% |
| SGEN | Sell | SEATTLE GENETICS INC | $1,983,000 | -45.2% | 35,000 | -25.5% | 0.13% | -43.5% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $1,386,000 | -34.5% | 12,700 | -3.1% | 0.09% | -32.1% |
| ENDP | Sell | ENDO INTL PLC | $1,244,000 | -66.0% | 170,392 | -21.6% | 0.08% | -64.7% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $1,181,000 | -16.7% | 30,317 | -1.6% | 0.08% | -13.3% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $1,015,000 | -35.8% | 10,600 | -5.4% | 0.07% | -33.0% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $1,018,000 | -13.6% | 24,000 | -4.0% | 0.07% | -10.7% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL INC | $965,000 | -60.3% | 22,200 | -30.3% | 0.06% | -59.1% |
| LH | Sell | LABORATORY CORP AMER HLDGS | $821,000 | -95.0% | 6,500 | -93.1% | 0.05% | -94.8% |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $793,000 | -45.9% | 76,500 | -3.7% | 0.05% | -44.1% |
| CLLS | Sell | CELLECTIS S Asponsored ads | $778,000 | -44.4% | 46,750 | -5.7% | 0.05% | -42.7% |
| MCK | Sell | MCKESSON CORP | $760,000 | -32.6% | 6,879 | -19.1% | 0.05% | -30.6% |
| PTCT | Sell | PTC THERAPEUTICS INC | $745,000 | -29.6% | 21,700 | -3.6% | 0.05% | -26.9% |
| XLRN | Sell | ACCELERON PHARMA INC | $623,000 | -32.8% | 14,300 | -11.7% | 0.04% | -30.5% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $626,000 | -45.3% | 6,429 | -3.0% | 0.04% | -43.8% |
| ITCI | Sell | INTRA CELLULAR THERAPIES INC | $599,000 | -49.5% | 52,600 | -3.7% | 0.04% | -48.0% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $501,000 | -29.4% | 25,650 | -3.8% | 0.03% | -26.7% |
| PINC | Sell | PREMIER INCcl a | $500,000 | -27.6% | 13,400 | -11.3% | 0.03% | -25.0% |
| VAR | Sell | VARIAN MED SYS INC | $354,000 | -49.8% | 3,122 | -50.4% | 0.02% | -48.9% |
| QURE | Sell | UNIQURE NV | $288,000 | -60.2% | 10,000 | -49.7% | 0.02% | -58.7% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $262,000 | -68.1% | 27,900 | -35.7% | 0.02% | -67.3% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $216,000 | -54.0% | 15,834 | -3.7% | 0.01% | -53.3% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $142,000 | -49.5% | 16,000 | -36.0% | 0.01% | -50.0% |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -18,000 | -100.0% | -0.08% | – |
| PFE | Exit | PFIZER INC | $0 | – | -29,200 | -100.0% | -0.08% | – |
| SYNH | Exit | SYNEOS HEALTH INCcl a | $0 | – | -26,156 | -100.0% | -0.09% | – |
| AET | Exit | AETNA INC NEW | $0 | – | -7,100 | -100.0% | -0.09% | – |
| TSRO | Exit | TESARO INC | $0 | – | -38,550 | -100.0% | -0.10% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -19,861 | -100.0% | -0.10% | – |
| IBB | Exit | ISHARES TRnasdaq biotech | $0 | – | -28,000 | -100.0% | -0.22% | – |
| ESRX | Exit | EXPRESS SCRIPTS HLDG CO | $0 | – | -44,500 | -100.0% | -0.27% | – |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -64,185 | -100.0% | -0.74% | – |
| PACB | Exit | PACIFIC BIOSCIENCES OF CALIF INC | $0 | – | -2,575,000 | -100.0% | -0.88% | – |
| KTWO | Exit | K2M GROUP HLDGS INC | $0 | – | -552,054 | -100.0% | -0.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.